|
Stage IIA Colon Cancer AJCC v7
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> ACT did not show substantial survival benefit in stage IIA colon cancer with elevated pretreatment serum CEA levels.
|
30815388 |
2019 |
|
Stage IIA Colon Cancer AJCC v8
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> ACT did not show substantial survival benefit in stage IIA colon cancer with elevated pretreatment serum CEA levels.
|
30815388 |
2019 |
|
malignant neoplasm of large intestine stage IIa
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> ACT did not show substantial survival benefit in stage IIA colon cancer with elevated pretreatment serum CEA levels.
|
30815388 |
2019 |
|
Pulmonary arterial hypertension
|
0.010 |
Biomarker
|
disease |
BEFREE |
(Study of Macitentan [ACT-064992] on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension [SERAPHIN]; NCT00660179; Selexipag [ACT-293987] in Pulmonary Arterial Hypertension [GRIPHON]; NCT01106014).
|
29447737 |
2018 |
|
Idiopathic pulmonary arterial hypertension
|
0.010 |
Biomarker
|
disease |
BEFREE |
(Study of Macitentan [ACT-064992] on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension [SERAPHIN]; NCT00660179; Selexipag [ACT-293987] in Pulmonary Arterial Hypertension [GRIPHON]; NCT01106014).
|
29447737 |
2018 |
|
Asthma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Asthma control was assessed per the 2012 GINA guidelines and the ACT questionnaire.
|
29724395 |
2018 |
|
Malaria, Vivax
|
0.010 |
Biomarker
|
disease |
BEFREE |
Plasmodium vivax malaria elimination can only be achieved by the deployment of 8-aminoquinolines (primaquine and tafenoquine) in combination with ACT to kill both blood and liver-stage parasites.
|
30674319 |
2019 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ACT serum levels were higher in women with AD that in female and male controls.
|
10629358 |
2000 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ACT measurements in cerebrospinal fluid from an additional 34 AD cases and 16 controls showed elevated levels (p = 0.02) in AD.
|
12509851 |
2003 |
|
Senile Plaques
|
0.010 |
Biomarker
|
disease |
BEFREE |
ACT is a major component of the senile plaques (SP) characteristic of Alzheimer's disease (AD).
|
15530656 |
2004 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
ACT is a major component of the senile plaques (SP) characteristic of Alzheimer's disease (AD).
|
15530656 |
2004 |
|
Presenile dementia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ACT has been shown to promote Abeta polymerization in vitro and in vivo, and levels of ACT protein in plasma and cerebrospinal fluid from Alzheimer's patients have been found to correlate with progression of dementia.
|
16987932 |
2006 |
|
Dementia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ACT has been shown to promote Abeta polymerization in vitro and in vivo, and levels of ACT protein in plasma and cerebrospinal fluid from Alzheimer's patients have been found to correlate with progression of dementia.
|
16987932 |
2006 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ACT levels were higher in AD patients than in CIND or controls.
|
18991685 |
2008 |
|
IMMUNE SUPPRESSION
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
ACT provides the opportunity to ameliorate immune suppression prior to transfer of tumor-reactive T cells to improve the therapeutic benefit.
|
29332158 |
2018 |
|
Sleeplessness
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
ACT-541468 is a novel dual orexin receptor antagonist (DORA) under development for the treatment of insomnia.
|
30284597 |
2019 |
|
Nasal Polyps
|
0.010 |
Biomarker
|
disease |
BEFREE |
ACT-774312 is an antagonist of the chemoattractant receptor-homologous molecule expressed on T helper (Th) 2 cells (CRTH2), in development for the treatment of nasal polyposis or other allergic and type-2 inflammatory diseases.
|
30589994 |
2019 |
|
Sleeplessness
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
ACT-541468 in elderly subjects was well tolerated and pharmacokinetics and pharmacodynamics are compatible with a drug for the treatment of insomnia.Clinicaltrials.gov: NCT02571855.
|
31642731 |
2020 |
|
Inclusion Body Myopathy, Sporadic
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A combination of different alpha1-ACT and ApoE genotypes appears not to enhance the risk of developing s-IBM.
|
15159602 |
2004 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A common polymorphism in the alpha 1-antichymotrypsin (ACT) gene has been found co modify the APOE*4-associated risk of Alzheimer's disease due to an apparent interaction between the two loci.
|
9129962 |
1997 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A common polymorphism in the alpha1-antichymotrypsin (ACT) gene is associated with Alzheimer's disease.
|
10474060 |
1999 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A common polymorphism in the alpha1-antichymotrypsin (ACT) gene has been shown to modify the Apolipoprotein E (ApoE) epsilon4-associated Alzheimer's disease (AD) risk identifying the combination of the ACT/AA and ApoE epsilon4/epsilon4 genotypes as a potential susceptibility marker for AD.
|
9572591 |
1998 |
|
Ovarian Failure, Premature
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A haplotype-based analysis of seven polymorphisms of the microRNA machinery genes for gene-gene interactions suggests that ***ACTA, ***GCCA, ***G*C*, *T*ATTA, and ***ACT* haplotypes (asterisk indicates SNP locus not included; DROSHA rs6877842 and rs10719, DICER1 rs13078 and rs3742330, RAN rs14035, and XPO5 rs2257082 and rs11077 polymorphisms) are associated with higher POI prevalence, and that ***GCTA, ***ACCA, *C*ATTA, and *C*ATT* haplotypes are associated with lower POI prevalence.
|
23549446 |
2013 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
A patient was found incidentally on dual-tracer (C-acetate [ACT] and F-FDG [FDG]) PET/CT for having crossed fused renal ectopia and 2 types of malignant tumors, colonic carcinoma and renal cell carcinoma (RCC), each having its own characteristic tracer avidity.
|
30608912 |
2019 |
|
Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A patient was found incidentally on dual-tracer (C-acetate [ACT] and F-FDG [FDG]) PET/CT for having crossed fused renal ectopia and 2 types of malignant tumors, colonic carcinoma and renal cell carcinoma (RCC), each having its own characteristic tracer avidity.
|
30608912 |
2019 |